Get a 2nd — and 3rd — opinion: 1 in 6 melanoma diagnoses could be wrong


Thursday, 06 July, 2017


Get a 2nd — and 3rd — opinion: 1 in 6 melanoma diagnoses could be wrong

When it comes to a melanoma diagnosis, it’s worth getting a second — or third — opinion.

Accurately diagnosing skin cancer is challenging pathologists to the point where more than one in six melanoma diagnoses could be wrong. Concerns over the accuracy of melanoma diagnoses have been raised in a study of US pathologists published by The BMJ.

The study was inspired by a researcher’s experience as a patient undergoing a skin biopsy, which resulted in three different independent interpretations, ranging from benign to invasive melanoma. A decade later, Professor Joann Elmore of the University of Washington School of Medicine in Seattle is healthy and overseeing research on the topic.

Previous studies have suggested high levels of diagnostic disagreement among pathologists when interpreting melanocytic lesions, but results were conflicting. So Dr Elmore, with a team of researchers, set out to measure the accuracy and reproducibility of pathologists’ diagnoses of melanocytic skin lesions.

The results showed that diagnoses can vary among pathologists, particularly for cases in the middle of the disease spectrum, suggesting the potential for both over- and under-diagnosis.

Melanoma is a type of skin cancer that develops from skin cells called melanocytes. Diagnosis relies on visual assessment of skin samples (biopsies) under a microscope by a pathologist, but the reliability of the criteria used to diagnose these skin lesions have never been established with rigorous standards.

The study had 187 practising pathologists from 10 US states independently interpret the same set of skin biopsy cases on two separate occasions (phases 1 and 2), at least eight months apart.

Each case had been independently reviewed by a panel of three experienced skin pathologists and a consensus reference diagnosis reached.

The results showed that diagnoses ranging from moderately atypical lesions to early-stage invasive melanoma were neither accurate nor reproducible.

The study concluded that efforts to improve clinical practice should include use of a standardised classification format, acknowledging uncertainty of specific diagnoses in pathology reports and development of more sophisticated diagnostic tools to support pathologists.

Image credit: ©stock.adobe.com/au/Damian Gretka

Originally published here.

Related Articles

GenesisCare expands with $35m Northern Beaches cancer centre

The relocated centre has expanded its services with a new radiation therapy offering and access...

In Conversation with Royal Women's Hospital CEO Sue Matthews

An hour after the final call for visitors to leave, Professor Sue Matthews — now CEO of...

Global prostate cancer rates predicted to double by 2040

The number of annual prostate cancer deaths worldwide is predicted to rise by 85% from 375,000 in...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd